LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

Home・Aandelen Lijst・Vivani Medical

Vivani Medical

Gesloten

1.19 -2.46

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.1400000000000001

Max

1.21

Belangrijke statistieken
By Trading Economics
Inkomsten	614K -6.5M
Werknemers	37

Dividenden
By Dow Jones
Volgende Winsten	30 mrt 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-21M 83M
Vorige openingsprijs	3.65
Vorige sluitingsprijs	1.19

Vivani Medical Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 mrt 2026, 18:43 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Kashkari Says Too Soon To Know Inflation Impact From Middle East Conflict

3 mrt 2026, 17:33 UTC

Acquisities, Fusies, Overnames

Ziff Davis to Sell Connectivity Division to Accenture for $1.2 Billion -- Update

3 mrt 2026, 23:45 UTC

Marktinformatie

Nikkei May Fall on Continued Concerns About Energy Costs -- Market Talk

3 mrt 2026, 23:44 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold Rises on Possible Dip-Buying Amid Ongoing Middle East Conflict -- Market Talk

3 mrt 2026, 23:25 UTC

Marktinformatie

Bannerman Energy Likely to Raise Less Equity for Uranium Projects -- Market Talk

3 mrt 2026, 23:25 UTC

Marktinformatie

Global Energy Roundup: Market Talk

3 mrt 2026, 22:38 UTC

Belangrijke Nieuwsgebeurtenissen

Iran Conflict Pushes Europe Toward Fresh Energy Crisis -- WSJ

3 mrt 2026, 22:16 UTC

Winsten

Berkshire Provides Scant Fourth-Quarter Financials. Investors Need to Do Their Own Calculations. -- Barrons.com

3 mrt 2026, 22:09 UTC

Winsten

Century Aluminum Changed Historical Method of Proportionately Consolidating Jamalco Production Assets to a Full Consolidation

3 mrt 2026, 22:06 UTC

Winsten

Century Aluminum: Accounting Change for 2023 and 2024 Doesn't Impact Net Income Attributable to Century Stockholders

3 mrt 2026, 22:05 UTC

Winsten

Century Aluminum Initially Concluded That an Accounting Change Was Immaterial, SEC Staff Disagreed With Company's Materiality Conclusion

3 mrt 2026, 22:03 UTC

Winsten

Century Aluminum to Restate Certain Results in Connection Wtih Accounting Change for Jamalco

3 mrt 2026, 21:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Tech, Media & Telecom Roundup: Market Talk

3 mrt 2026, 21:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

3 mrt 2026, 21:45 UTC

Belangrijke Nieuwsgebeurtenissen

The Iran War Puts the Fed's Rate-Cut Timeline in Doubt -- Barrons.com

3 mrt 2026, 21:37 UTC

Winsten

EVgo Stock Rises as Earnings Defy EV Slump. The Rest of 2026 Doesn't Look So Rosy. -- Barrons.com

3 mrt 2026, 21:26 UTC

Belangrijke Nieuwsgebeurtenissen

Freeport McMoRan Stock Slides as the Mideast Conflict Hits Commodities -- Barrons.com

3 mrt 2026, 20:31 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

U.S. Natural Gas Gains on Middle East Turmoil, Weather Outlook -- Market Talk

3 mrt 2026, 20:04 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Futures Pull Back as Trump Offers Shipping Protection -- Market Talk

3 mrt 2026, 19:17 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold and Silver Drop as Energy Surges -- Market Talk

3 mrt 2026, 18:43 UTC

Winsten

Berkshire CEO Abel Is Fond of Financial Metric Similar to One Criticized by Buffett -- Barrons.com

3 mrt 2026, 18:29 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Global Energy Roundup: Market Talk

3 mrt 2026, 18:29 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Norsk Hydro Announces Stoppage of Qatar Aluminum Smelter -- Market Talk

3 mrt 2026, 18:22 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Kashkari on March Projections: Had a Lot of Confidence Up Until a Few Days Ago

3 mrt 2026, 18:22 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Kashkari: Too Soon to Know Impact Iran Conflict Will Have on Inflation

3 mrt 2026, 18:17 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Strait of Hormuz Standstill Keeps Bid in Oil Futures -- Market Talk

3 mrt 2026, 18:14 UTC

Winsten

How Long Can Anthropic Play Defense? -- WSJ

3 mrt 2026, 17:41 UTC

Belangrijke Nieuwsgebeurtenissen

Exxon Is Down Since the Iran Conflict. These Energy Stocks Are Bigger Winners. -- Barrons.com

3 mrt 2026, 17:36 UTC

Belangrijke Nieuwsgebeurtenissen

Iran Conflict is Starting to Boost Gasoline Prices -- Update

3 mrt 2026, 17:28 UTC

Acquisities, Fusies, Overnames

Tinicum, Blackstone to Make Decision on Offer By End of Day March 31

Peer Vergelijking

Prijswijziging

Vivani Medical Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

Buy

Hold

Sell

Gebaseerd op 0 analisten die aandelenratings hebben gegeven aan Vivani Medical - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Winst voor belastingen

Verkoop

Operationele winst

Over Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.